• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胶质母细胞瘤辅助治疗后 O6-甲基鸟嘌呤-DNA 甲基转移酶启动子甲基化和 MGMT 蛋白表达的变化。

Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.

机构信息

Department of Neurosurgery, Chonnam National University Hwasun Hospital, Gwangju, Republic of Korea.

出版信息

Oncol Rep. 2010 May;23(5):1269-76. doi: 10.3892/or_00000760.

DOI:10.3892/or_00000760
PMID:20372840
Abstract

The aim of this study was to evaluate variations of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and protein expression after adjuvant treatment in glioblastoma patients. Sixteen patients with a glioblastoma underwent 34 microsurgeries including 18 re-operations. After surgery, patients underwent follow-up with radiotherapy and chemotherapy (temozolomide, ACNU and cisplatin) between 2000 and 2008. To investigate MGMT methylation and MGMT expression, methylation-specific PCR (MSP) and immunohistochemical staining (IHC) were performed. The methylation status of the MGMT promoter was altered in five (27.8%) of 18 re-operation specimens. In four specimens, the MGMT promoter was found to be methylated after primary surgery, but was found to be unmethylated on post-treatment samples. MGMT protein expression was altered in 15 (83.3%) of 18 cases. Fifteen specimens showed higher levels of protein expression as compared to previous samples and three samples demonstrated a similar expression pattern. After irradiation and exposure to steroid and temozolomide 6 and 24 h later, a methylated MGMT promoter and negative protein expression were seen in U343 glioblastoma cell lines which have methylated promoter and negative protein expression. Variations in MGMT promoter methylation and protein expression can occur after treatment. We suggest that changes of MGMT promoter methylation and protein expression might not be related to a direct effect of irradiation and exposure to steroid and temozolomide.

摘要

本研究旨在评估胶质母细胞瘤患者在辅助治疗后 O6-甲基鸟嘌呤-DNA 甲基转移酶(MGMT)启动子甲基化和蛋白表达的变化。16 名胶质母细胞瘤患者接受了 34 次微创手术,其中 18 次为再次手术。手术后,患者于 2000 年至 2008 年间接受了放疗和化疗(替莫唑胺、ACNU 和顺铂)的随访。为了研究 MGMT 甲基化和 MGMT 表达,进行了甲基化特异性 PCR(MSP)和免疫组织化学染色(IHC)。在 18 个再次手术标本中,有 5 个(27.8%)的 MGMT 启动子甲基化状态发生了改变。在 4 个标本中,MGMT 启动子在初次手术后被发现甲基化,但在治疗后样本中被发现是非甲基化的。在 18 例中,有 15 例(83.3%)MGMT 蛋白表达发生了改变。与之前的样本相比,15 个标本的蛋白表达水平升高,3 个标本表现出相似的表达模式。在 U343 胶质母细胞瘤细胞系中,MGMT 启动子在接受照射和暴露于类固醇和替莫唑胺 6 和 24 小时后发生甲基化,且蛋白表达为阴性,这些细胞系的 MGMT 启动子为甲基化且蛋白表达为阴性。MGMT 启动子甲基化和蛋白表达在治疗后可能发生变化。我们认为,MGMT 启动子甲基化和蛋白表达的变化可能与照射、暴露于类固醇和替莫唑胺的直接作用无关。

相似文献

1
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.胶质母细胞瘤辅助治疗后 O6-甲基鸟嘌呤-DNA 甲基转移酶启动子甲基化和 MGMT 蛋白表达的变化。
Oncol Rep. 2010 May;23(5):1269-76. doi: 10.3892/or_00000760.
2
Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.MGMT 基因启动子甲基化状态不能预测替莫唑胺联合顺铂治疗胶质母细胞瘤患者的临床结局。
Neuropathology. 2009 Aug;29(4):443-9. doi: 10.1111/j.1440-1789.2008.00998.x. Epub 2009 Jan 6.
3
O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.启动子超甲基化和免疫组织化学表达的 O(6)-甲基鸟嘌呤 DNA 甲基转移酶与胶质母细胞瘤患者的无进展生存期相关。
Int J Clin Oncol. 2010 Aug;15(4):352-8. doi: 10.1007/s10147-010-0065-6. Epub 2010 Mar 16.
4
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.O6-甲基鸟嘌呤-DNA 甲基转移酶蛋白表达和启动子甲基化的联合分析为胶质母细胞瘤的预后提供了优化的预测。
Neuro Oncol. 2013 Mar;15(3):370-81. doi: 10.1093/neuonc/nos308. Epub 2013 Jan 17.
5
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子甲基化与儿童胶质母细胞瘤的生存获益及对替莫唑胺的敏感性相关。
Pediatr Blood Cancer. 2007 Apr;48(4):403-7. doi: 10.1002/pbc.20803.
6
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.MGMT 启动子甲基化状态和 MGMT 及 CD133 免疫组化表达作为替莫唑胺联合放疗治疗胶质母细胞瘤患者的预后标志物。
J Transl Med. 2012 Dec 17;10:250. doi: 10.1186/1479-5876-10-250.
7
The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.胶质母细胞瘤中MGMT启动子甲基化与MGMT蛋白的相关性及预后意义
Neurosurgery. 2009 Nov;65(5):866-75; discussion 875. doi: 10.1227/01.NEU.0000357325.90347.A1.
8
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.胶质母细胞瘤中连续样本中O(6)-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子甲基化的变化
J Neurooncol. 2008 Mar;87(1):71-8. doi: 10.1007/s11060-007-9486-0. Epub 2007 Nov 15.
9
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.O-6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子甲基化状态可预测新诊断的胶质母细胞瘤患者同步放化疗后假性进展的发生率及预后。
J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163.
10
MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.MGMT 基因启动子甲基化作为替莫唑胺为基础的放化疗治疗胶质母细胞瘤的一种潜在预后因素:单机构研究。
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):661-7. doi: 10.1016/j.ijrobp.2011.12.086. Epub 2012 Mar 11.

引用本文的文献

1
Advanced Distance-Resolved Evaluation of the Perienhancing Tumor Areas with FLAIR Hyperintensity Indicates Different ADC Profiles by Promoter Methylation Status in Glioblastoma.基于液体衰减反转恢复序列高信号对胶质母细胞瘤瘤周强化区域进行高级距离分辨评估:依据启动子甲基化状态显示不同的表观扩散系数特征
AJNR Am J Neuroradiol. 2025 Feb 3;46(2):302-310. doi: 10.3174/ajnr.A8493.
2
Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.MGMT 启动子甲基化检测对替莫唑胺治疗胶质母细胞瘤患者总生存期的预测价值。
Cochrane Database Syst Rev. 2021 Mar 12;3(3):CD013316. doi: 10.1002/14651858.CD013316.pub2.
3
Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features.
初发性和复发性脑胶母细胞瘤的启动子甲基化状态:与 DWI 和 DSC PWI 特征的相关性研究。
AJNR Am J Neuroradiol. 2021 May;42(5):853-860. doi: 10.3174/ajnr.A7004. Epub 2021 Feb 25.
4
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.新诊断的低级别胶质瘤中 MGMT 启动子甲基化水平是复发时发生高频突变的预测因子。
Neuro Oncol. 2020 Nov 26;22(11):1580-1590. doi: 10.1093/neuonc/noaa059.
5
Changes of O-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse-A Meta-Analysis Type Literature Review.胶质母细胞瘤复发中O-甲基鸟嘌呤DNA甲基转移酶(MGMT)启动子甲基化的变化——一项Meta分析类文献综述
Cancers (Basel). 2019 Nov 21;11(12):1837. doi: 10.3390/cancers11121837.
6
The impact of adjuvant radiotherapy on molecular prognostic markers in gliomas.辅助放疗对胶质瘤分子预后标志物的影响。
Onco Targets Ther. 2019 Mar 26;12:2215-2224. doi: 10.2147/OTT.S200818. eCollection 2019.
7
Glioblastoma Recurrence and the Role of O-Methylguanine-DNA Methyltransferase Promoter Methylation.胶质母细胞瘤复发与O-甲基鸟嘌呤-DNA甲基转移酶启动子甲基化的作用
JCO Clin Cancer Inform. 2019 Feb;3:1-12. doi: 10.1200/CCI.18.00062.
8
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.克服胶质母细胞瘤替莫唑胺耐药性的潜在策略
Neurol Med Chir (Tokyo). 2018 Oct 15;58(10):405-421. doi: 10.2176/nmc.ra.2018-0141. Epub 2018 Sep 21.
9
Cell-specific pattern of berberine pleiotropic effects on different human cell lines.小檗碱对不同人源细胞系多效作用的细胞特异性模式。
Sci Rep. 2018 Jul 13;8(1):10599. doi: 10.1038/s41598-018-28952-3.
10
Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas.根据递归划分分析进行分层可预测新诊断胶质母细胞瘤的预后。
Oncotarget. 2017 Jun 27;8(26):42974-42982. doi: 10.18632/oncotarget.17322.